5-Fluorouracil: mechanisms of action and clinical strategies
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU exerts its anti-cancer effects by inhibiting thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA [4].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“5-FU mainly destroys the deoxynucleotide pool required for DNA replication by inhibiting thymidylate synthase (TS), and mixes its metabolites into RNA and DNA to exert anti-tumor effects [4,127].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“MutSα recognizes and associates with FdU:G mismatch pairs in an in vitro binding experiment”
From Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress (2014) · cites this paper as [210]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 1×
“Irinotecan is a topoisomerase I inhibitor and is active in the first- and second-line treatment of advanced colorectal cancer, in which it has shown improved survival and quality of life when compared with best supportive care in patients who have failed 5-FU/L”
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Research works printed but not linked: 2
- Rutman, R. J., Cantarow, A. & Paschkis, K. E. Studies on 2-acetylaminofluorene carcinogenesis: III. The utilization of uracil-2-C14 by pre–neoplastic rat liver. Cancer Res. 14, 119 (1954).
- Jackson, R. C. & Grindley, G. B. The Biochemical Basis for Methotrexate Cytotoxicity (eds Sirotnak, F. M., Burchall, J. J., Ensminger, W. D. & Montgomery, J. A.) 289–315 (Academic, New York, 1984).
Cited by
Items 901–1,000 of 1,028
The Human Replicative Helicase, the CMG Complex, as a Target for Anti-cancer Therapy
Seo, Y., & Kang, Y. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00026 · Cited by 56
“Gemcitabine and 5-FU have been widely used to treat several cancers (Longley et al., 2003; Brown et al., 2014).”
BackgroundDumont, A., de Rosny, C., Kieu, T., Perrey, S., Berger, H., Fluckiger, A., Muller, T., de Barros, J.-P. P., Pichon, L., Hichami, A., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1723-x · Cited by 56
Inhibiting eukaryotic ribosome biogenesis
Awad, D., Prattes, M., Kofler, L., Rössler, I., Loibl, M., Pertl, M., Zisser, G., Wolinski, H., Pertschy, B., & Bergler, H. (2019) · BMC Biology · doi:10.1186/s12915-019-0664-2 · Cited by 70
Azimee, S., Rahmati, M., Fahimi, H., & Moosavi, M. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117466 · Cited by 56
Xiang, D., Yang, J., Xu, Y., Zhang, S., Li, M., Chen, Z., Zhang, C., & Liu, D. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117612 · Cited by 54
The Premature Senescence in Breast Cancer Treatment Strategy
Milczarek, M. (2020) · Cancers · doi:10.3390/cancers12071815 · Cited by 62
“The authors summarized that overexpression of CIP2A was responsible for the tumor resistance to senescence-inducting chemotherapy [40].”
BackgroundHarnessing DNA Replication Stress for Novel Cancer Therapy
Zhu, H., Swami, U., Preet, R., & Zhang, J. (2020) · Genes · doi:10.3390/genes11090990 · Cited by 60
“Gemcitabine (irreversibly) and hydroxyurea (reversibly) inhibit ribonucleotide reductase [23], while 5-fluorouracil inhibits thymidylate synthetase [24].”
BackgroundErdoğan, M. K., Ağca, C. A., & Aşkın, H. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2021.1900301 · Cited by 59
“5-fluorouracil (5-FU) (Figure 1a), is an antimetabolite chemotherapy agent and widely used in treatment of many cancer such as colorectal, pancreas, ovary, brain, breast and liver, alone or combination with therapeutic agents (3).”
BackgroundUgorji, O. L., Umeh, O. N. C., Agubata, C. O., Adah, D., Obitte, N. C., & Chukwu, A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12369 · Cited by 53
“In the gastrointestinal tract, 5-FU is known to be degraded by enzymes making oral administration erratic and unreliable [15, 16, 17].”
BackgroundPotential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review
Rabaan, A. A., Sulaiman, T., Al-Ahmed, S. H., Buhaliqah, Z. A., Buhaliqah, A. A., AlYuosof, B., Alfaresi, M. S., Fares, M. A. A., Alwarthan, S. M., Alkathlan, M. S., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12030608 · Cited by 66
“The common classes of antimetabolites include purine antagonists (6-mercaptopurine) [44] and pyrimidine antagonists (5-fluorouracil) [45].”
BackgroundShin, M. C., Zhang, J., Min, K. A., Lee, K., Moon, C., Balthasar, J. P., & Yang, V. C.-M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.08.030 · Cited by 54
“Although 5-FU still remains the primary choice for treatment, its therapeutic effect is strictly limited (10–15% response rate and at most 6–8 months extension of life-span) [4,5].”
BackgroundNucleolar control of p53: a cellular Achilles’ heel and a target for cancer therapy
Vlatković, N., Boyd, M. T., & Rubbi, C. P. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1361-x · Cited by 57
Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line
Takahashi, K., Tanaka, M., Inagaki, A., Wanibuchi, H., Izumi, Y., MIURA, K., NAGAYAMA, K., Shiota, M., & Iwao, H. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2135 · Cited by 55
Paraptosis and NF-κB activation are associated with protopanaxadiol-induced cancer chemoprevention
Wang, C., Li, B., Wen, X., Zhang, Z., Yu, C., Calway, T., He, T., Du, W., & Yuan, C. (2013) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-13-2 · Cited by 54
“5-Fluorouracil (5-FU) is a chemotherapeutic agent widely used for cancers of different organs including colorectum [28].”
BackgroundXiao, Z., Ko, H. L., Goh, E. H., Wang, B., & Ren, E. C. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt085 · Cited by 53
“Moreover, as 5-FU induces the expression of the tumor suppressor p53 (34), whether the cause and effect of hnRNP K downregulation is dependent on p53 status requires further clarification.”
BackgroundAdvancements in Pharmacotherapy for Noncancerous Manifestations of HPV
Kollipara, R., Ekhlassi, E., Downing, C. P., Guidry, J. A., Lee, M., & Tyring, S. K. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4050832 · Cited by 53
“This leads to inhibition of DNA and RNA synthesis, which prevents cellular replication and proliferation [42,43].”
BackgroundA Density Functional Theory Study on the Interaction Between 5-Fluorouracil Drug and C24 Fullerene
Hosseinian, A., Vessally, E., Yahyaei, S., Edjlali, L., & Bekhradnia, A. (2017) · Journal of Cluster Science · doi:10.1007/s10876-017-1253-6 · Cited by 54
A Metabolic Engineering Approach to Incorporate Modified Pyrimidine Nucleosides into Cellular RNA
Zhang, Y., & Kleiner, R. E. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b11449 · Cited by 58
Precision treatment in colorectal cancer: Now and the future
Yau, T. O. (2019) · JGH Open · doi:10.1002/jgh3.12153 · Cited by 61
Alnuqaydan, A. M., Rah, B., Almutary, A. G., & Chauhan, S. S. (2020) · PubMed Central · Cited by 76
Park, S. R., Namkoong, S., Friesen, L., Cho, C., Zhang, Z. Z., Chen, Y., Yoon, E., Kim, C. H., Kwak, H., Kang, H. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108077 · Cited by 57
“5FU is known to induce RNA damage (Longley et al., 2003), which could compromise cellular protein quality and provoke endoplasmic reticulum (ER) stress.”
BackgroundEpithelial-Mesenchymal Transition and MicroRNAs in Colorectal Cancer Chemoresistance to FOLFOX
Escalante, P. I., Quiñones, L. A., & Contreras, H. R. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010075 · Cited by 54
“5-FU can also be metabolized by orotate phosphoribosyltransferase (OPRT) int 5-FU metabolites that are i corporated into the RNA and DNA of the c ll, accounting to a le ser exte t for 5-FU cyt toxicity.”
BackgroundResultInfluentialSaccharomyces cerevisiae as a model system to study the response to anticancer agents
Matuo, R., Sousa, F. G., Soares, D. G., Bonatto, D., Saffi, J., Escargueil, A. E., Larsen, A. K., & Henriques, J. A. P. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1937-4 · Cited by 70
“This is particularly true for 5-FU, topotecan, irinotecan, cytarabine and gemcitabine, among others [5, 56, 118].”
BackgroundLong Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer
Campos-Parra, A. D., López–Urrutia, E., Moreno, L. T. O., López‐Camarillo, C., Meza‐Menchaca, T., Figueroa‐González, G., Bustamante-Montes, L. P., & Pérez‐Plasencia, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092711 · Cited by 53
“The compound 5-FU is an analog of uracil with a fluorine atom at the C-5 position, and its mechanism of action involves the inhibition of thymidylate synthase and the incorporation of its metabolites into RNA and DNA, thus inhibiting their normal function [84].”
BackgroundSafarpour, S., Pirzadeh, M., Ebrahimpour, A., Shirafkan, F., Madani, F., Hosseini, S. M., Moghadamnia, A. A., & Kazemi, S. (2022) · BioMed Research International · doi:10.1155/2022/2273000 · Cited by 52
Research progress of colon-targeted oral hydrogel system based on natural polysaccharides
Wang, D., Wang, W., Wang, P., Wang, C., Niu, J., Liu, Y., & Chen, Y. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123222 · Cited by 53
Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer
Cotino‐Nájera, S., Herrera, L. A., Domínguez-Gómez, G., & Díaz‐Chávez, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1287505 · Cited by 58
Adamczyk, O., Szota, M., Rakowski, K., Prochownik, M., Doveiko, D., Chen, Y., & Jachimska, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010037 · Cited by 57
“In particular, it inhibits the activity of the enzyme thymidylate synthase (TS) [17].”
BackgroundOne carbon metabolism and its implication in health and immune functions
Dang, S., Jain, A., Dhanda, G., Bhattacharya, N., Bhattacharya, A., & Senapati, S. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3926 · Cited by 59
Pharmacogenomics of fluorouracil-based chemotherapy toxicity
Matsusaka, S., & Lenz, H. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1027684 · Cited by 52
“1 Genetic variation in TYMS TS is an enzyme that catalyzes the transformation of dUMP, which is essential for DNA replication [14].”
BackgroundDun, J., Chen, X., Gao, H., Zhang, Y., Zhang, H., & Zhang, Y. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215573396 · Cited by 58
“This effect ultimately reduces cell growth by inhibiting the cell’s ability to synthesize DNA; thus, 5-FU is an S-phase-specific drug.(33) In our study, Res led to S-phase arrest, but the cell cycle distribution was only slightly altered when the cells were treated with 5-FU alone or in a combination of the two drugs.”
BackgroundKrishnaiah, Y. S. R., & Khan, M. A. (2012) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2012.696268 · Cited by 54
“The bioactivation of 5-FU to 5-fluoro-2′deoxyuridine disrupts RNA synthesis and the action of thymidylate synthase, and thereby kills cancer cells.([62]) At the same time, 5-FU is also subjected to bioinactivation by dihydrouracil dehydrogenase in the liver and mucosal membrane of the GI tract.”
BackgroundInositol Polyphosphate Multikinase Is a Coactivator of P53-Mediated Transcription and Cell Death
Xu, R., Sen, N., Paul, B. D., Snowman, A. M., Rao, F., Vandiver, M. S., Xu, J., & Snyder, S. H. (2013) · Science Signaling · doi:10.1126/scisignal.2003405 · Cited by 52
Human rpL3 plays a crucial role in cell response to nucleolar stress induced by 5-FU and L-OHP
Esposito, D., Crescenzi, E., Sagar, V., Loreni, F., Russo, A., & Russo, G. (2014) · Oncotarget · doi:10.18632/oncotarget.2591 · Cited by 55
“In addition, development of drug resistance during the therapy remains a major problem [9].”
BackgroundOccurrence, Ecotoxicology, and Treatment of Anticancer Agents as Water Contaminants
Xie, H. (2012) · Journal of Environmental & Analytical Toxicology · doi:10.4172/2161-0525.s2-002 · Cited by 52
“5-Fluorouracil and capecitabine as a prodrug of 5-fluorouracil are shown to inhibit exosome complex [42].”
BackgroundNemec, M. J., Kim, H., Marciante, A. B., Barnes, R. C., Talcott, S. T., & Mertens‐Talcott, S. U. (2016) · Food & Function · doi:10.1039/c6fo00636a · Cited by 56
MicroRNA-33a and let-7e inhibit human colorectal cancer progression by targeting ST8SIA1
Shan, Y., Liu, Y., Zhao, L., Liu, B., Li, Y., & Li, J. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.07.016 · Cited by 53
Wang, J., Feng, W., Zhang, S., Chen, L., Sheng, Y., Tang, F., He, J., Xu, X., Ao, H., & Peng, C. Y. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.111887 · Cited by 56
Satapathy, S. R., & Sjölander, A. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.023 · Cited by 52
Hong, S., Cai, W., Huang, Z., Wang, Y., Mi, X., Huang, Y., Lin, Z., & Chen, X. (2020) · Oncology Reports · doi:10.3892/or.2020.7728 · Cited by 52
“These adverse effects limit its clinical application and further improvements in the efficacy of chemotherapy are needed (20,22).”
BackgroundAngiogenesis is promoted by exosomal DPP4 derived from 5-fluorouracil-resistant colon cancer cells
Zheng, X., Liu, J., Li, X., Tian, R., Shang, K., Dong, X., & Cao, B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.009 · Cited by 59
Characterization of 5-Fluorouracil-Resistant Cholangiocarcinoma Cell Lines
Namwat, N., Amimanan, P., Loilome, W., Jearanaikoon, P., Sripa, B., Bhudhisawasdi, V., & Tassaneeyakul, W. (2008) · Chemotherapy · doi:10.1159/000151541 · Cited by 52
“5-Fluorouracil (5-FU) is a standard chemotherapeutic agent used to treat many types of cancers [”
BackgroundNovel opportunities for thymidylate metabolism as a therapeutic target
Wilson, P. M., Fazzone, W., LaBonte, M. J., Deng, J. N., Neamati, N., & Ladner, R. D. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0280 · Cited by 53
“in the treatment of a range of cancers, including breast cancers, and cancers of the aerodigestive and gastrointestinal tract (1).”
BackgroundInfluentialAntiangiogenic and Antitumoral Activity of Phenyl-3-(2-Chloroethyl)Ureas
Petitclerc, É., Deschesnes, R. G., Côté, M., Marquis, C., Janvier, R., Lacroix, J., Miot-Noirault, É., Legault, J., Mounetou, E., Madelmont, J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3715 · Cited by 54
“Notably, 5-FU is also used in the treatment of other neoplastic diseases such as breast, aerodigestive tracts, and head/neck cancers (48).”
BackgroundMultifunctional Enzyme Packaging and Catalysis in the Qβ Protein Nanoparticle
Fiedler, J. D., Fishman, M. R., Brown, S. D., Lau, J. L., & Finn, M. G. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00885 · Cited by 51
Pathway Analysis for Drug Repositioning Based on Public Database Mining
Pan, Y., Cheng, T., Wang, Y., & Bryant, S. H. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci4005354 · Cited by 57
“■ ABBREVIATIONS ABAT, 4-aminobutyrate aminotransferase; ADOR, adenosine receptor; ALDH, aldehyde dehydrogenase; AR, androgen receptor; CA2, carbonic anhydrase II; COX2, cytochrome c oxidase subunit II; CRABP2, cellular retinoic acid binding protein 2; CYP2J2, cytochrome P450, family 2, subfamily J, polypeptide 2; DUT,…”
BackgroundInfluentialSolier, S., Zhang, Y., Ballestrero, A., Pommier, Y. G., & Zoppoli, G. M. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912800190901 · Cited by 56
Gade, T. P. F., Buchanan, I. M., Motley, M. W., Mazaheri, Y., Spees, W. M., & Koutcher, J. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0611 · Cited by 53
Huehls, A. M., Huntoon, C. J., Joshi, P. M., Baehr, C., Wagner, J. M., Wang, X., Lee, M. Y., & Karnitz, L. M. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.100164 · Cited by 53
“…not only disrupts DNA metabolism after it is converted into intracellular FdUrd, but it also disturbs RNA metabolism (after conversion into 5-FUTP) (Longley et al., 2003), an effect that may contribute to 5-FU’s efficacy in human tumors but that would complicate the mechanistic studies described…”
BackgroundMethodInfluentialPharmacogenomics of Scopoletin in Tumor Cells
Seo, E., Saeed, M. E. M., Law, B. Y. K., Wu, A., Kadioglu, O., Greten, H. J., & Efferth, T. (2016) · Molecules · doi:10.3390/molecules21040496 · Cited by 51
Colon cancer targeting using conjugates biomaterial 5-flurouracil
Jaferian, S., Negahdari, B., & Eatemadi, A. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.10.004 · Cited by 54
Song, X., Ren, T., Zheng, Z., Lu, T., Wang, Z., Du, F., & Tong, H. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.10.112 · Cited by 51
Horo, H., Das, S., Mandal, B., & Kundu, L. M. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.10.095 · Cited by 54
Qiu, Y., Dai, Y., Zhang, C., Yang, Y., Jin, M. L., Shan, W., Shen, J., Lü, M., Tang, Z., Ju, L., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1005-y · Cited by 51
Cocrystal of 5-Fluorouracil: Characterization and Evaluation of Biopharmaceutical Parameters
Gautam, M. K., Besan, M., Pandit, D., Mandal, S. K., & Chadha, R. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1360-9 · Cited by 51
Justino, P. F. C., Franco, Á. X., Pontier-Bres, R., Monteiro, C. E. D. S., Barbosa, A. L. D. R., de Souza, M. H. L. P., Czerucka, D., & Soares, P. M. G. (2019) · Cytokine · doi:10.1016/j.cyto.2019.154791 · Cited by 53
Li, H., Ma, X., Yang, D., Suo, Z., Dai, R., & Liu, C. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29370 · Cited by 51
“Cisplatin was used as the first line chemotherapeutic agent for GC treatment.(3,4) Nevertheless, acquired resistance to cisplatin is a main barrier to the effective treatment for GC.”
MethodCaminiti, M. F., El-Rabbany, M., Jeon, J. Y., & Bradley, G. (2020) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2020.07.215 · Cited by 51
“14 Inhibition of TS deprives actively proliferating cells of thymidine, thereby inducing lethal DNA damage 14 (Fig 1).”
BackgroundHodroj, K., Barthélémy, D., Lega, J., Grenet, G., Gagnieu, M., Walter, T., Guitton, J., & Payen, L. F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100125 · Cited by 57
“Different mechanisms of 5-FU activation into cytotoxic nucleotides have been described.(12,13) One of them is the conversion of 5-FU to 5-fluoro-deoxyuridine monophosphate (FdUMP) that inhibits the enzyme thymidylate synthase (TS).”
BackgroundColchicine Ameliorates 5‐Fluorouracil‐Induced Cardiotoxicity in Rats
Safarpour, S., Safarpour, S., Pirzadeh, M., Moghadamnia, A. A., Ebrahimpour, A., Shirafkan, F., Mansoori, R., Kazemi, S., & Hosseini, S. M. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6194532 · Cited by 51
“5-FU exerts its anticancer impacts in a number of ways, including inhibition of the thymidylate synthase enzyme [3, 4] and activation of protein p53, as well as an effect on cell cycle regulation and G1/S arrest [5].”
BackgroundThe transcription factor LSF: a novel oncogene for hepatocellular carcinoma.
Santhekadur, P. K., Rajasekaran, D., Siddiq, A., Gredler, R., Chen, D., Schaus, S. E., Hansen, U. M., Fisher, P. B., & Sarkar, D. (2012) · Europe PMC (PubMed Central) · Cited by 62
Sakai, H., Sagara, A., Matsumoto, K., Jo, A., Hirosaki, A., Takase, K., Sugiyama, R., Sato, K., Ikegami, D., Horie, S., et al. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.05.012 · Cited by 54
“5-fluorouracil (5-FU) is idely used to treat malignant tumors due to its ability to improve he tumor-free status and survival rates [3].”
BackgroundThe RNA Exosome Component hRrp6 Is a Target for 5-Fluorouracil in Human Cells
Kammler, S., Lykke‐Andersen, S., & Jensen, T. H. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2217 · Cited by 51
“Recent research suggests that the 5-FU effect might be exerted through its incorporation into cellular RNA (7, 8).”
BackgroundThe mismatch repair‐mediated cell cycle checkpoint response to fluorodeoxyuridine
Liu, A., Yoshioka, K., Salerno, V., & Hsieh, P. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21824 · Cited by 50
“The FP anti-metabolite 5-fluoro-20-uridine (FU) is an anti-cancer drug widely used in the treatment of advanced colorectal cancer [Longley et al., 2003].”
BackgroundDecreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance
Humeniuk, R., Menon, L. G., Mishra, P. J., Gorlick, R., Sowers, R., Rode, W., Pizzorno, G., Cheng, Y.-C., Kemeny, N., Bertino, J. R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0716 · Cited by 50
“A low expression of TP gene and high expression of DPD also have been correlated with resistance to 5-FU (27).”
BackgroundThe role of metabolic reprogramming in pancreatic cancer chemoresistance
Liu, C., Li, C., & Liu, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1108776 · Cited by 59
“5-Fluorouracil (5-Fu) is a thymidylate synthase (TS) inhibitor that interferes with tumor cell DNA synthesis and incorporates metabolites into RNA to impair protein synthesis (Longley et al., 2003).”
BackgroundAn Introduction to Fundamentals of Cancer Biology
Sriharikrishnaa, S., Suresh, P. S., & Kabekkodu, S. P. (2023) · Biological and medical physics, biomedical engineering · doi:10.1007/978-3-031-31852-8_11 · Cited by 77
Grasso, G., Colella, F., Forciniti, S., Onesto, V., Iuele, H., Siciliano, A. C., Carnevali, F., Chandra, A., Gigli, G., & del Mercato, L. L. (2023) · Nanoscale Advances · doi:10.1039/d3na00218g · Cited by 56
An RNA damage response network mediates the lethality of 5-FU in colorectal cancer
Chen, J.-K., Merrick, K. A., Kong, Y. W., Izrael-Tomasevic, A., Eng, G. M., Handly, E. D., Patterson, J. C., Cannell, I. G., Suárez-López, L., Hosios, A. M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101778 · Cited by 57
“18 Whether these damaged RNAs significantly contribute to 5-FU cytotoxicity in mammalian tumors or are cleared from RNA pools with negligible cytotoxic effects remains a topic of active debate.”
InfluentialKazemi, A., Afshari, M. H., Baesmat, H., Keshavarz, S., Zeinali, F., Zahiri, S., Torabi, E., Manteghi, F., & Rohani, S. (2025) · Journal of Polymers and the Environment · doi:10.1007/s10924-025-03496-6 · Cited by 58
“By blocking thymidylate synthase, 5-FU lowers the availability of thymidine for DNA synthesis, resulting in decreased DNA replication and ultimately inducing cell death [47 ].”
Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice
Generoso, S. D. V., Rodrigues, N. M., Trindade, L. M., Paiva, N. C., Cardoso, V. N., Carneiro, C. M., Ferreira, A. V. M., Faria, A. M. C., & Maioli, T. U. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0052-z · Cited by 53
“This phenomenon occurs because anti-metabolite agents, such as 5-fluorouracil (5-FU), exert their functions in cells that are in the S phase of the cell cycle, inhibiting the synthesis of essential components of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), interrupting cell proliferation [14, 15].”
BackgroundRole of N-terminal residues in the ubiquitin-independent degradation of human thymidylate synthase
Peña, M. M. O., Xing, Y., Koli, S., & Berger, F. G. (2006) · Biochemical Journal · doi:10.1042/bj20051479 · Cited by 54
Heterogeneity of glycolysis in cancers and therapeutic opportunities
Warmoes, M. O., & Locasale, J. W. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.019 · Cited by 55
“Of note, current chemotherapies used in the clinic disrupt a large number of biological processes that sustain cancer development and growth [66–71].”
BackgroundKim, K.-Y., Yi, B.-R., Lee, H.-R., Kang, N.-H., Jeung, E., Kim, S. U., & Choi, K. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1288 · Cited by 50
“Several drugs are being used in gastric cancer therapy including 5-fluorouracil (5-FU) or its analog capecitabine, BCNU (carmustine) as well as methylCCNU (semustine), doxorubicin (Adriamycin), mitomycin C, cisplatin and Taxotere (3,4).”
BackgroundEgodawatte, S., Dominguez, S., & Larsen, S. C. (2016) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2016.09.024 · Cited by 51
Mitani, S., Kadowaki, S., Komori, A., Sugiyama, K., Narita, Y., Taniguchi, H., Ura, T., Ando, M., Sato, Y., Yamaura, H., et al. (2017) · Medicine · doi:10.1097/md.0000000000006874 · Cited by 54
Yang, B., Shen, M., Liu, J., & Ren, F. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2253-9 · Cited by 50
“However, 5-FU has a rather narrow therapeutic index and a short half-life in vivo (in a matter of minutes) (33,34), and is associated with substantial side effects on the bone marrow, gastrointestinal tract, leukocytes, and platelets (35–37).”
BackgroundWang, Y., Dansette, P. M., Pigeon, P., Top, S., McGlinchey, M. J., Mansuy, D., & Jaouen, G. (2017) · Chemical Science · doi:10.1039/c7sc04213b · Cited by 51
Zhang, Z., Feng, L., Liu, P., & Duan, W. (2018) · Bioscience Reports · doi:10.1042/bsr20180620 · Cited by 51
RetractedAnticancer therapeutic effect of cerium-based nanoparticles: known and unknown molecular mechanisms
Amaldoss, M. J. N., Mehmood, R., Yang, J., Koshy, P., Kumar, N., Unnikrishnan, A., & Sorrell, C. C. (2022) · Biomaterials Science · doi:10.1039/d2bm00334a · Cited by 51
A novel drug delivery of 5-fluorouracil device based on TiO 2 /ZnS nanotubes
Faria, H. A. M., & de Queiroz, Á. A. A. (2015) · Materials Science and Engineering C · doi:10.1016/j.msec.2015.06.008 · Cited by 51
“11) [43].”
Gupta, K. K., Pal, N., Mishra, P. K., Srivastava, P., Mohanty, S., & Maiti, P. (2014) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.34932 · Cited by 50
Derenzini, M., Donati, G., Mazzini, G., Montanaro, L., Vici, M., Ceccarelli, C., Santini, D., Taffurelli, M., & Treré, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2065 · Cited by 53
Ahsan, F., Yar, M., Gulzar, A., & Ayub, K. (2022) · Journal of nanostructure in chemistry · doi:10.1007/s40097-022-00474-5 · Cited by 51
“FU is proved to be effective against colorectal, head, neck, and breast cancer [9, 14].”
BackgroundWang, Y., Yung, P. S., Lü, G., Liu, Y., Ding, C., Mao, C., Li, Z. A., & Tuan, R. S. (2024) · Advanced Materials · doi:10.1002/adma.202401334 · Cited by 60
Adams, S. C., Schondorf, R., Benoit, J., & Kilgour, R. D. (2015) · BMC Cancer · doi:10.1186/s12885-015-1418-3 · Cited by 55
Synthesis and biological activity of salinomycin conjugates with floxuridine
Huczyński, A., Antoszczak, M., Kleczewska, N., Lewandowska, M., Maj, E., Stefańska, J., Wietrzyk, J., Janczak, J., & Celewicz, L. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.045 · Cited by 49
“Since its first discovery in 1957, 5fluorouracil (FUra) has been a well-known anti-tumour agent used in the treatment of several neoplastic diseases, such as colon or breast cancers [9,10].”
BackgroundRole of TheMTHFRPolymorphisms in Cancer Risk Modification and Treatment
Kim, Y. (2009) · Future Oncology · doi:10.2217/fon.09.26 · Cited by 56
“com 529 future science group to f luoro-b-ureidopropionate by dihydropyrimidinase and subsequently to f luoro-balanine by b-ureidopropionase (Figure 2) [74,82].”
BackgroundInfluentialHua, X., Hou, X., Gong, X., & Shen, G. (2013) · Analytical Methods · doi:10.1039/c3ay40149a · Cited by 53
Xu, B., Guo, X., Mathew, S., Armesilla, A. L., Cassidy, J., Darling, J. L., & Wang, W. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.10.013 · Cited by 49
“Although the response rates for advanced CRC has been improved to 40–50% by combination of 5-FU with other anti-cancer drugs [1], there are less than 12% of advanced CRC patients, who have received systemic 5-FU chemotherapy, still alive after 2 years [2].”
BackgroundYi, B.-R., Hwang, K.-A., Aboody, K. S., Jeung, E., Kim, S. U., & Choi, K. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.09.010 · Cited by 49
let-7b and let-7c are determinants of intrinsic chemoresistance in renal cell carcinoma
Peng, J., Mo, R., Ma, J., & Fan, J. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-015-0596-4 · Cited by 50
“5-FU-based chemotherapy improves overall and disease-free survival of patients with above cancers [17].”
BackgroundHuehls, A. M., Wagner, J. M., Huntoon, C. J., Geng, L., Erlichman, C., Patel, A. G., Kaufmann, S. H., & Karnitz, L. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0814 · Cited by 54
Tai, C., Wang, C., Tai, C.-J., Lin, Y.-F., Lin, C.-S., Jian, J., Chang, Y., & Chang, C. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/514719 · Cited by 62
“The currently recommended chemotherapeutic drug for colorectal cancer is 5-fluorouracil (5-Fu) [3, 14–16], which activates apoptosis by incorporation of DNA/RNA on cancer cells [17].”
de la Cueva, A., de Molina, A. R., Álvarez-Ayerza, N., Ramos, M. A., Cebrián, A., del Pulgar, T. G., & Lacal, J. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064961 · Cited by 50
“a range of cancers, including CRC, breast and head and neck cancers [3,4].”
BackgroundZhang, Y.-T. Y., Zhu, X., Huang, T., Chen, L., Liu, Y., Li, Q., Song, J., Ma, S., Zhang, K., Yang, B., et al. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.08.010 · Cited by 51
Uncovering Large-Scale Conformational Change in Molecular Dynamics without Prior Knowledge
Melvin, R. L., Godwin, R. C., Xiao, J., Thompson, W. G., Berenhaut, K. S., & Salsbury, F. R. (2016) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6b00757 · Cited by 57
Tsuda, M., Terada, K., Ooka, M., Kobayashi, K., Sasanuma, H., Fujisawa, R., Tsurimoto, T., Yamamoto, J., Iwai, S., Kadoda, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16508 · Cited by 50
“Three anti-cancer chemotherapeutic drugs, Cytosine arabinoside (Ara-C, cytarabine), 5-Fluorouracil (5-FU) and Trifluridine (FTD), are efficiently incorporated into genomic DNA during DNA replication [1, 2].”
BackgroundSharma, A., Kaur, A., Jain, U. K., Chandra, R., & Madan, J. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.04.020 · Cited by 51
Zhang, Y., Li, C.-C., Tang, B., & Zhang, C. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b01655 · Cited by 49
Metadata
- Authors
- Longley, D. B., Harkin, D. P., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Johnston, Patrick G.
- ORCID
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2003-05
- Volume
- 3
- Issue
- 5
- Pages
- 330-338
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984328540
- Cited by
- 5,332
- References
- 111
- Citations by year
- 2026: 293 · 2025: 350 · 2024: 391 · 2023: 377 · 2022: 435 · 2021: 398 · 2020: 408 · 2019: 324 · 2018: 299 · 2017: 289 · 2016: 257 · 2015: 251 · 2014: 221 · 2013: 193 · 2012: 154
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- 5-fluorouracil, mechanism of action, drug resistance, predictive biomarkers, chemotherapeutic target, anticancer activity, cancer chemotherapy
- MeSH terms
- Animals, Antimetabolites, Antineoplastic, Fluorouracil, Humans, Interferons, Oxidoreductases, RNA, Thymidine Phosphorylase, Thymidylate Synthase, Biomarkers, Tumor Suppressor Protein p53, Microsatellite Repeats, Oligonucleotide Array Sequence Analysis, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.